Lantheus Acquires Life Molecular Imaging (Life Molecular) for $350M Upfront

Lantheus Holdings completed its previously announced acquisition of Life Molecular Imaging Ltd., a subsidiary of Life Healthcare Group Holdings Ltd. The deal includes an upfront payment of $350 million and (per the earlier definitive agreement) up to $400 million in potential earn-out and milestone payments, and strengthens Lantheus’s commercial and R&D capabilities in Alzheimer’s PET diagnostics with Neuraceq (florbetaben F18).